While existing treatments primarily focus on hemodynamic modifications through ACE inhibitors, ARBs, and SGLT2 inhibitors, M-SYFSY directly targets the metabolic dysfunction underlying diabetic kidney disease pathogenesis. This evidence concerns the gene ACE and diabetic kidney disease.